Novo VP Weighs In on Approval of Lilly's Obesity Pill

Jamey Millar, executive vice president, US Operations of Novo Nordisk, reacts to Eli Lilly's once-daily weight-loss pill, called Foundayo, winning FDA approval on "Bloomberg The Close." -------- More on Bloomberg Television and Markets Like this video?